StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Regenxbio's operating cash flow for the twelve months ending Jun 30, 2026 was -$246.67M. For fiscal 2025 it was -$123.96M. The highest annual figure on record is $218.88M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$123.96M–
FY2024Dec 31, 2024-$173.13M–
FY2023Dec 31, 2023-$218.41M–
FY2022Dec 31, 2022-$207.49M-194.8%
FY2021Dec 31, 2021$218.88M–
FY2020Dec 31, 2020-$54.06M–
FY2019Dec 31, 2019-$107.71M-202.9%
FY2018Dec 31, 2018$104.65M–
FY2017Dec 31, 2017-$57.99M–
FY2016Dec 31, 2016-$48.56M–
FY2015Dec 31, 2015-$22.52M–
FY2014Dec 31, 2014-$2.40M–
FY2013Dec 31, 2013-$3.01M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$62.24M–
Q1 FY2026Mar 31, 2026-$76.19M-326.5%
Q4 FY2025Dec 31, 2025-$52.29M–
Q3 FY2025Sep 30, 2025-$55.96M–
Q2 FY2025Jun 30, 2025-$49.34M–
Q1 FY2025Mar 31, 2025$33.63M–
Q4 FY2024Dec 31, 2024-$31.62M–
Q3 FY2024Sep 30, 2024-$40.55M–
Q2 FY2024Jun 30, 2024-$45.50M–
Q1 FY2024Mar 31, 2024-$55.46M–
Q4 FY2023Dec 31, 2023-$40.76M–
Q3 FY2023Sep 30, 2023-$49.41M–
Q2 FY2023Jun 30, 2023-$47.32M–
Q1 FY2023Mar 31, 2023-$80.92M–
Q4 FY2022Dec 31, 2022-$39.37M-111.5%
Q3 FY2022Sep 30, 2022-$50.46M–
Q2 FY2022Jun 30, 2022-$61.75M–
Q1 FY2022Mar 31, 2022-$55.91M–
Q4 FY2021Dec 31, 2021$341.50M+765.3%
Q3 FY2021Sep 30, 2021-$42.50M–
Q2 FY2021Jun 30, 2021-$36.07M–
Q1 FY2021Mar 31, 2021-$44.05M–
Q4 FY2020Dec 31, 2020$39.47M–
Q3 FY2020Sep 30, 2020-$36.46M–
Q2 FY2020Jun 30, 2020-$21.50M–
Q1 FY2020Mar 31, 2020-$35.57M–
Q4 FY2019Dec 31, 2019-$25.51M–
Q3 FY2019Sep 30, 2019-$29.15M–
Q2 FY2019Jun 30, 2019-$23.75M-133.8%
Q1 FY2019Mar 31, 2019-$29.30M-150.4%
Q4 FY2018Dec 31, 2018-$4.14M–
Q3 FY2018Sep 30, 2018-$19.56M–
Q2 FY2018Jun 30, 2018$70.21M–
Q1 FY2018Mar 31, 2018$58.13M–
Q4 FY2017Dec 31, 2017-$13.83M–
Q3 FY2017Sep 30, 2017-$17.14M–
Q2 FY2017Jun 30, 2017-$9.55M–
Q1 FY2017Mar 31, 2017-$17.48M–
Q4 FY2016Dec 31, 2016-$20.42M–
Q3 FY2016Sep 30, 2016-$11.82M–

More Regenxbio figures

See a number that looks wrong?